- Professor, CWRU School of Medicine
Rina Lazebnik, MD, is Chief of the Division of General Pediatrics and Adolescent Medicine, Medical Director of the Pediatric Practice and Adolescent Medicine at University Hospitals Rainbow Babies & Children’s Hospital.
Dr. Lazebnik is board certified in pediatrics and adolescent medicine. Her special interests are pediatric and adolescent gynecology and general adolescent medicine. She was named to the UH Rainbow Babies & Children’s Hospital medical staff in 1989.
Dr. Lazebnik is a graduate of Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel. She served her residency in pediatrics at Haddasa-Rokach Hospital, Tel-Aviv, and a fellowship in adolescent medicine at MetroHealth Medical Center, Cleveland, Ohio.
In addition to her more than 10 years of volunteer service to The Free Clinic of Cleveland, Dr. Lazebnik has served on the Advisory Board for Starting Out Healthy “Under the Rainbow” at Rainbow Babies & Children’s Hospital for more than 10 years. She has published nearly three dozen papers in medical journals, contributed chapters to two medical handbooks and presented research abstracts at nearly four dozen medical meetings and conferences.
Dr. Lazebnik is a member of the American Academy of Pediatrics; Ambulatory Pediatric Association, Ohio Valley Chapter; Society for Adolescent Medicine; North American Society for Pediatric and Adolescent Gynecology and Society for Adolescent Medicine.
Honors and Recognition
Numerous teaching awards
Obesity, immunizations, contraception
- Adolescent Medicine
English, Hebrew, Hungarian, Romanian
- Adolescent Medicine - American Board of Pediatrics
- Pediatrics - American Board of Pediatrics
Fellowship | Adolescent Medicine - Pediatric
Adolescent Medicine - Pediatric - Cleveland Metropolitan General Hospital (1987 - 1989)
Residency | Pediatrics
Pediatrics - The Tel Aviv Sourasky Medical Center (1977 - 1982)
Sackler School Of Medicine (1977)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Rina Lazebnik did not disclose any Outside Relationships with Industry.